Trials Sponsors Conditions Drugs Pricing

Conditions

CD30-Positive Peripheral T-Cell Lymphoma

Keywords

Peripheral T-Cell LymphomaCD30Brentuximab VedotinBV-CHPReal-World EvidenceObservational Study

Outcome Measures

Primary Outcomes (1)

Progression-Free Survival (PFS)
Progression-free survival of brentuximab vedotin plus CHP as first-line treatment in adult participants with CD30-positive peripheral T-cell lymphoma, defined as the time from registration until disease progression or relapse, or death from any cause. Initiation of the subsequent line of therapy is considered an event
From enrollment until disease progression, relapse, death, or last follow-up, assessed up to approximately 68 months.

Secondary Outcomes (6)

Overall Response Rate (ORR) and Complete Response (CR) as Efficacy Outcomes
During first-line treatment, assessed up to approximately 12 months
Overall Survival (OS)
From enrollment until disease progression, relapse, death, or last follow-up, assessed up to approximately 68 months.
Incidence and Type of Treatment-Related Adverse Events
During first-line treatment, assessed up to approximately 12 months
CD30 Expression at Diagnosis
At diagnosis (baseline
Treatment Response Assessed by Interim and End-of-Treatment PET/CT
During first-line treatment, assessed up to approximately 12 months
+1 more secondary outcomes

Study Arms (1)

BV-CHP First-Line Treatment Cohort

This cohort includes adult participants diagnosed with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) as first-line treatment as part of routine clinical practice in Spain. Data are collected retrospectively from medical records to evaluate treatment outcomes and safety in a real-world setting.

Drug: Brentuximab Vedotin Plus CHP

Interventions

Brentuximab Vedotin Plus CHPDrug

Brentuximab vedotin administered in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) as first-line treatment according to routine clinical practice. The treatment was prescribed by the treating physician as part of standard medical care and was not assigned or modified by the study

BV-CHP First-Line Treatment Cohort

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The study population consists of adult patients (18 years of age or older) diagnosed with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) as first-line treatment in routine clinical practice in Spain. All patients were treated between January 2019 and September 2024 and were identified retrospectively through review of existing medical records, including the RELINF registry of the GELTAMO group. No treatment interventions or assignments were made as part of the study.

You may qualify if:

Sponsors & Collaborators

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Otherlead
Takeda
Industrycollaborator

Study Sites (37)

Hospital Universitario A Coruña

A Coruña, A Coruña, 15006, Spain

RECRUITING

DANIEL GARCIA GARCIACONTACT

DANIEL GARCIA GARCIAPRINCIPAL INVESTIGATOR

Hospital Universitari Son Llàtzer

Palma de Mallorca, Balearic Islands, 07008, Spain

RECRUITING

RAQUEL DEL CAMPOCONTACT

RAQUEL DEL CAMPOPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Lymphoma, T-Cell, Peripheral

Interventions

Brentuximab Vedotinsomatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)-

Condition Hierarchy (Ancestors)

Lymphoma, T-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Eva Domingo Domenech, MD

CONTACT

932697750 edomingo@iconcologia.net

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 27, 2026

First Posted

June 3, 2026

Study Start

February 15, 2026

Actual (reported)

Primary Completion

November 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (1)

BV-CHP First-Line Treatment Cohort

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (37)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (6)

Study Arms (1)

BV-CHP First-Line Treatment Cohort

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (37)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations